
- Telehealth Visits
- Insurance plan information
- Provider Type: Physician

Nghiem B. Ha, MD, MAS
Transplant Hepatology • Hepatology- Telehealth Visits
- Insurance plan information
- Provider Type: Physician



Nghiem B. Ha, MD, MAS
Transplant Hepatology • HepatologyOn this page
About me
Dr. Nghiem B. Ha is a gastroenterologist and transplant hepatologist who cares for patients with liver diseases, including those awaiting liver transplantation.
In his research, Ha focuses on finding ways to better manage chronic liver disease by studying body composition with an advanced technique called quantitative morphometrics. In particular, he is working to develop strategies for accurately assessing and addressing abnormalities involving muscle mass and abdominal fat to improve care and outcomes for patients with chronic liver disease.
Ha earned his medical degree and master of advanced studies degree in clinical research at the University of California, Davis School of Medicine and UC Davis Health Clinical and Translational Science Center. At UCSF, he completed a residency in internal medicine, followed by a fellowship in gastroenterology as part of a program with the American Board of Internal Medicine that integrates research training with training in patient care. He also completed a fellowship in advanced/transplant hepatology at UCSF.
Ha is a member of the American Association for the Study of Liver Diseases, American Society of Transplantation, American Gastroenterological Association, American College of Gastroenterology and Northern California Society for Clinical Gastroenterology.
Education & training
Board certification
- Transplant Hepatology, American Board of Internal Medicine
- Gastroenterology, American Board of Internal Med/Gastroenterology
- Internal Medicine, American Board of Internal Medicine
Fellowship
- Transplant Hepatology, UCSF School of Medicine -GME
- Gastroenterology, UCSF School of Medicine -GME
Residency
- Internal Medicine, UCSF School of Medicine -GME
Degree
- MD, University of California Davis School of Medicine
Academic title
- Health Sciences Clinical Professor
My expertise
Locations
My research
Clinical trials
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)Opens in a new window
Recruiting
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not it is co...
Publications
Showing 1-6 of 111 reviews
- September 26, 20265 out of 5 Stars
Dr Ha is one of THE BEST doctors I have ever had. He is bright, analytical, evidence based, educational, and so very kind. He is not rushed. Recaps our plan before ending the visit. One of UCSFs finest. I have total trust in him.
- September 26, 20265 out of 5 Stars
Dr Ha is a great guy he explained my condition and the treatment options very clearly with alacrity and humor
- September 23, 20265 out of 5 Stars
He listened and he taught me what to monitor. He explained my condition using examples which is very helpful. He also showed me what are the factors that lead to his decision on what kind of care I should have. I really appreciate this in-person meeting.
- September 22, 20265 out of 5 Stars
Excellent
- September 22, 20265 out of 5 Stars
Dr. Ha is very knowledgeable, engaging and encouraging. I feel well cared for
- September 16, 20265 out of 5 Stars
Dr Ha is one of the most caring dr I have encountered during my cancer journey. He is concerned about how I am feeling asks me questions and is a great listener. I would recommend him highly.
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.
The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.